Stephen Stahl
Carlsbad, CANPI 1710144167
Payments from drug & device makers
$1,409,281in general payments, 2019–2025
Across 398 payments — averaging $3540.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$435K
- Takeda Pharmaceuticals U.S.A., Inc.$382K
- AbbVie$82K
- H. Lundbeck A S$72K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66K
- Alkermes, Inc.$60K
- plus $311K from 24 others
What the payments were for
- Consulting fees$253,56518%
- Speaking & faculty fees$693,39649%
- Grants$379,00827%
- Travel & lodging$75,7795%
- Food & beverage$7,4081%
- Education$1240%
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 37 | $435,246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $382,230 |
| AbbVie(2 entities) | 59 | $82,194 |
| H. Lundbeck A S | 24 | $72,212 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $66,316 |
| Alkermes, Inc. | 40 | $60,365 |
| Acadia Pharmaceuticals Inc | 50 | $58,629 |
| Teva Pharmaceuticals USA, Inc. | 16 | $42,856 |
| E.r. Squibb & Sons, L.L.C. | 14 | $28,829 |
| Otsuka America Pharmaceutical, Inc. | 20 | $22,711 |
| Cipla USA Inc. | 1 | $20,000 |
| Sage Therapeutics, LLC | 17 | $19,144 |
| Janssen Research & Development, LLC | 2 | $17,878 |
| Daiichi Sankyo Company LTD | 2 | $15,000 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $13,039 |
| Tris Pharma Inc | 6 | $11,500 |
| Neurocrine Biosciences, Inc. | 7 | $11,398 |
| Supernus Pharmaceuticals, Inc. | 5 | $10,895 |
| Pfizer | 3 | $9,781 |
| Livanova USA, Inc. | 2 | $6,109 |
| Upjohn US 1 LLC | 1 | $4,500 |
| Axsome Therapeutics, Inc. | 2 | $4,322 |
| Sanofi-aventis U.S. LLC | 1 | $4,165 |
| Merck | 2 | $3,720 |
| Neos Therapeutics, LP | 2 | $2,375 |
| Boehringer Ingelheim | 1 | $1,780 |
| Bausch Health US, LLC | 1 | $1,000 |
| Eli Lilly | 1 | $500 |
| Biomarin Pharmaceutical Inc. | 1 | $492 |
| Eisai Inc. | 4 | $96 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRINTELLIX$295,470
- LATUDA$208,586
- SEP-225289$200,000
- ARISTADA$97,501
- VRAYLAR$81,743
- CAPLYTA$65,676
- BRINTELLIX$61,009
- REXULTI$59,215
- NUPLAZID$46,951
- AUSTEDO$42,767
- LYBALVI$26,799
- ARISTADA INITIO$23,875
- ESCITALOPRAM$16,447
- LIPITOR$8,008
- COBENFY$6,354
- DISEASE EDUCATION$6,250
- INGREZZA$6,180
- VNS Therapy Symmetry Model 8103 Generator$6,109
- Auvelity$4,322
- AMBIEN$4,165
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.